USAntibiotics

What USAntibiotics does

USAntibiotics, LLC is a U.S. pharmaceutical manufacturer headquartered in Bristol, Tennessee, that operates the only FDA-approved U.S. production site for oral-dose amoxicillin and amoxicillin-clavulanate antibiotics (branded Amoxil and Augmentin). The company owns 12 New Drug Applications covering immediate and extended-release tablets, capsules, and oral suspensions across the Amoxil, Augmentin, Augmentin XR, and Augmentin ES-600 product lines. Its 394,000-square-foot facility on more than 40 acres is cGMP-compliant, DSCSA-serialized, and designated by the Department of Homeland Security as critical manufacturing infrastructure, with annual capacity to produce 2.2 billion tablets and 312 million capsules — equivalent to roughly 100% of U.S. amoxicillin demand and several billion doses in packaged form.

The company was founded in 1978, acquired out of bankruptcy by Jackson Healthcare in April 2021, and resumed full production in late 2021 under the leadership of President Patrick Cashman, whose prior roles included senior leadership at Pfizer, SmithKline Beecham, and Lundbeck Canada. Product launches in 2025 included the first-ever approval under the FDA Commissioner's National Priority Voucher pilot program — Augmentin XR (December 2025), returning extended-release amoxicillin-clavulanate to the U.S. market for the first time since 2011. Distribution is conducted through enterprise partnerships with Walmart Pharmacies and McKesson via the ClarusONE Sourcing Services joint venture, supplying pharmacies, health systems, and providers nationwide.

USAntibiotics generates revenue through B2B channel sales of branded and authorized-generic finished dose antibiotic products, with no public pricing disclosure (typical of prescription pharmaceuticals). The customer base is concentrated in two main distribution channels — Walmart and McKesson — that together reach the bulk of U.S. retail and institutional pharmacy demand. Within the broader category of U.S. antibiotics, Amoxil and Augmentin alone account for over 30% of annual prescriptions, and approximately 1 in 12 Americans are prescribed an amoxicillin product each year, anchoring a structurally large and recurring demand base for the company's domestic, on-peninsula manufacturing output.

Name

USAntibiotics

Legal name

USAntibiotics, LLC

Website

https://us-antibiotics.com

Company type

Private

Founded year

1978

Operating status

Operating

Headcount range

11–50 employees

Short description

USAntibiotics is the only FDA-approved U.S. manufacturer of amoxicillin and amoxicillin-clavulanate antibiotics (Amoxil and Augmentin), operating a 394,000-square-foot cGMP facility in Bristol, Tennessee that supplies tablets, capsules, and oral suspensions through Walmart and McKesson distribution partnerships.

Ownership category

akta.pro rank

Product category

Generic Antibiotic Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

Keywords

• Generic antibiotics manufacturing
• Amoxicillin production
• Finished dosage forms
• Penicillin beta-lactam antibiotics
• Pharmaceutical contract manufacturing

Headquarters

HQ city

Bristol

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Antibiotic product sales: USAntibiotics manufactures and sells amoxicillin-based antibiotics (Amoxil and Augmentin brand products and authorized generics) through distribution partnerships with Walmart and McKesson. The company produces tablets, capsules, and powders for oral suspension in various dosages and pack sizes.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

USAntibiotics manufactures and supplies Amoxil (amoxicillin) and Augmentin (amoxicillin-clavulanate) finished dosage antibiotic products — including tablets, capsules, and powders for oral suspension — at its 394,000 sq ft Bristol, Tennessee facility. The company is the only U.S. manufacturer of these antibiotics and sells its products to pharmacies, health systems, and healthcare providers through distribution partnerships with Walmart and McKesson.

Product overview

USAntibiotics is the only U.S. manufacturer of amoxicillin and amoxicillin clavulanate antibiotics (branded as Amoxil and Augmentin), operating the country's only FDA-approved production facility for these oral dose antibiotics. The company produces a portfolio of finished dosage forms including tablets, capsules, and powders for oral suspension. The product portfolio includes Amoxil (amoxicillin), Augmentin (amoxicillin clavulanate), Augmentin XR (extended-release combination), and Augmentin ES-600 (extended-spectrum suspension), alongside authorized generic equivalents. With 12 New Drug Applications (NDAs), the company offers multiple formulations and pack sizes to meet nationwide demand for these essential antibiotics.

Differentiator

Problem solved

Functional benefit

Products and services

• Augmentin XR (Amoxicillin and Clavulanate Potassium Extended-Release) Extended-release oral antibacterial combination tablet (1,000 mg/62.5 mg) indicated for the treatment of community-acquired pneumonia and acute bacterial sinusitis in adult and pediatric patients. Taken twice daily compared to three-times-daily conventional formulations for improved patient adherence.
• Amoxicillin and Clavulanate Potassium Tablet (Augmentin)
• Amoxicillin and Clavulanate Potassium for Oral Suspension Powder for oral suspension available in multiple strengths (250 mg/62.5 mg per 5 mL, 125 mg/31.25 mg per 5 mL) for pediatric and adult reconstitution and dosing.
• Amoxil (Amoxicillin) Capsules Immediate-release amoxicillin capsule (500 mg) for oral administration. Brand-name Amoxil, the #1 prescribed antibiotic in the U.S. and among the top 20 medicines prescribed annually.
• Amoxicillin for Oral Suspension Oral suspension formulation of amoxicillin alone (400 mg per 5 mL) supplied as powder for reconstitution, for pediatric and adult use.
• Augmentin ES-600 (Amoxicillin-Clavulanate Oral Suspension) Extended-spectrum formulation of amoxicillin-clavulanate for oral suspension (600 mg/42.9 mg per 5 mL) included in the company's 12 NDAs. Indicated for pediatric and adult patients requiring higher-dose beta-lactam therapy.

Quantifiable outcome

• FDA first-ever National Priority Voucher approval for Augmentin XR (December 2025)
• +2 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Four partnerships are on record, tiered core and flagship.

• WalmartcoreChannel Partner/ Reseller/ Distributor · 8 September 2025USAntibiotics collaborates with Walmart to provide domestically manufactured antibiotics directly to American families through Walmart pharmacies. The collaboration aligns with Walmart's pledge to invest an additional $350 billion in products made, grown, or assembled in the United States by 2030.
• McKessoncoreChannel Partner/ Reseller/ Distributor · 8 September 2025USAntibiotics partners with McKesson for nationwide distribution of domestically manufactured antibiotics to pharmacies, health systems, and healthcare providers. McKesson's digitally connected distribution network strengthens the U.S. pharmaceutical supply chain and healthcare access.
• ClarusONE Sourcing ServicescoreChannel Partner/ Reseller/ Distributor · 8 September 2025ClarusONE Sourcing Services is a joint venture partner that works with USAntibiotics and McKesson to build a resilient supply chain while meeting the needs of the communities served. Hanna Watson serves as President of ClarusONE.
• Jackson HealthcareflagshipOthers · 19 April 2021Jackson Healthcare, a family of highly specialized healthcare staffing, search, and technology companies, purchased USAntibiotics out of bankruptcy in April 2021. Jackson Healthcare is the parent company of USAntibiotics, providing strategic ownership and support. Founded in 2000, Jackson Healthcare helps healthcare facilities serve more than 10 million patients each year with over 1,500 associates and over $1.4 billion in annual revenue.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Market position

Strengths4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@USAntibiotics
• LinkedInlinkedin.com/company/usantibiotics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about USAntibiotics